BridgeBio Pharma, Inc. (BBIO) Stock
BBIO Key Statistics
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
CEO: Neil Kumar. Company website
BBIO — Frequently Asked Questions
What is the BBIO stock price today?
BridgeBio Pharma, Inc. (BBIO) trades at $66.61, down 1.04% on the day, as of Sep 20, 2026 14:57 UTC.
What is BridgeBio Pharma, Inc.'s market cap?
BridgeBio Pharma, Inc. has a market capitalisation of $13.05B, calculated from the live BBIO share price and shares outstanding.
What is the P/E ratio of BBIO?
BBIO has no meaningful price-to-earnings ratio: BridgeBio Pharma, Inc. lost $3.58 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does BridgeBio Pharma, Inc. make?
BridgeBio Pharma, Inc. generated revenue of $691.84M over the trailing twelve months, which puts the stock at 18.86 times sales.
What is the 52-week range for BBIO?
BBIO has traded between $48.78 and $93.42 over the past 52 weeks, and the last price is 28.7% below that high.
Is BridgeBio Pharma, Inc. profitable?
No. BridgeBio Pharma, Inc. is loss-making, with a net margin of -100.64% over the trailing twelve months.
What is the analyst price target for BBIO?
Wall Street analysts rate BBIO Buy, with an average price target of $110.09, 65.3% above the current price.
What sector is BridgeBio Pharma, Inc. in?
BridgeBio Pharma, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of BridgeBio Pharma, Inc.?
Neil Kumar is the chief executive of BridgeBio Pharma, Inc., which employs 999 people.
Where can I track BBIO in real time?
QFI Terminal shows BBIO with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See BBIO live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open BBIO in Terminal See plans